Knight Therapeutics (GUD) Stock Price, News & Analysis

Company Overview

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

Key Stats

• Today's Range: C$5.75 to C$5.79
• 50-Day Range: C$5.75 to C$6.54
• 52-Week Range: C$5.09 to C$6.55
• Volume: 24,670 shs
• Average Volume: 63,365 shs
• Market Capitalization: C$575.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: C$7.15
• Consensus Rating: Buy

Knight Therapeutics Stock Analysis - MarketRank™

Knight Therapeutics scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Buy

Consensus Rating

Knight Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Knight Therapeutics has a consensus price target of C$7.15, representing about 23.7% upside from its current price of C$5.78.

Amount of Analyst Coverage

Knight Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Knight Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Knight Therapeutics is -21.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Due to a projected decrease in earnings for Knight Therapeutics, their PEG ratio cannot be calculated.

Price to Book Value per Share Ratio

Knight Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GUD.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Knight Therapeutics does not currently pay a dividend.

Dividend Growth

Knight Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GUD.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Knight Therapeutics has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Knight Therapeutics this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Knight Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.62% of the stock of Knight Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 17.89% of the stock of Knight Therapeutics is held by institutions.

GUD Stock Analysis - Frequently Asked Questions

How have GUD shares performed this year?

Knight Therapeutics' stock was trading at C$5.34 on January 1st, 2025. Since then, GUD shares have increased by 8.2% and is now trading at C$5.78.

How do I buy shares of Knight Therapeutics?

Shares of GUD stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Knight Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Knight Therapeutics investors own include ARC Resources (ARX), Cenovus Energy (CVE), Enbridge (ENB), Whitecap Resources (WCP), Bombardier, Inc. Class B (BBD.B), Crescent Point Energy (CPG) and Suncor Energy (SU).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:GUD
• CIK: N/A
• Web: www.gud-knight.com
• Phone: 514-484-4483
• Fax: N/A
• Employees: 725
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Knight Therapeutics: C$7.15
• High Price Target: C$7.50
• Low Price Target: C$6.50
• Potential Upside/Downside: +23.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 57.26
• P/E Growth: -1013.5
• Net Income: -C$30.73 million
• Net Margins: -8.81%
• Pretax Margin: N/A
• Return on Equity: -4.04%
• Return on Assets: 0.51%

Debt

• Debt-to-Equity Ratio: 7.52
• Current Ratio: 3.36
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: C$384.56 million
• Price / Sales: 1.50
• Cash Flow: C$1.50 per share
• Price / Cash Flow: 3.85
• Book Value: C$7.65 per share
• Price / Book: 0.76

Miscellaneous

• Outstanding Shares: 99,653,000
• Free Float: N/A
• Market Cap: C$575.99 million
• Optionable: Not Optionable
• Beta: 0.05